PITTSBORO, NC--(Marketwire - February 07, 2008) - Biolex Therapeutics, Inc. today announced the commencement of patient dosing in a United States Phase 2a clinical trial of its lead product candidate Locteron for the treatment of hepatitis C. As a controlled-release interferon alfa, Locteron is designed to improve patient care through a more favorable side-effect profile and more convenient patient dosing compared to existing pegylated interferon products and Albuferon®, each of which lack a controlled-release mechanism. The U.S. Phase 2a trial is designed to expand upon the favorable results of the SELECT-1 European Phase 2a trial announced November 6, 2007, at the 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) conference.
